Table 3 Ongoing trials with immunotherapy in HER2 + metastatic breast cancer patients
From: Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives
Drug | Phase | Setting | Status | Type of intervention | Mechanism of action | |
|---|---|---|---|---|---|---|
NCT02492711 [91] | Margetuximab | III | Metastatic | Completed | HER2-block enhancer | Increased ADCC effect |
NCT03330561 [96] | PRS-343 | I | Metastatic | Recruiting | Immune costimulatory | T-Cell activation |
NCT03650348 [97] | PRS-343+ Atezolizumab | I | Metastatic | Recruiting | Immune costimulatory+ Immune check point inhibitor | T-Cell activation+ Anti PD-L1 |
NCT02829372 [98] | NA | I | Metastatic | Recruiting | Immune costimulatory (anti HER2/ CD-3 antibody) | ADCC + T-Cell activation |
NCT02627274 [100] | RO6874281⁞ | I | Metastatic | Recruiting | Immune costimulatory | ADCC + T-Cell activation |
DIAmOND [101] | Durvalumab+ Tremelimumab+ Trastuzumab | II | Metastatic | Recruiting | Immune check point inhibitor | Anti PD-L1 + Anti-CTLA-4 |
NCT03414658 [102] | Avelumab + Utomilumab + Vinroelbine+ Trastuzumab | II | Metastatic | Recruiting | Immune costimulatory+ Immune check point inhibitor | T-Cell activation+ Anti PD-1 |
NCT03199885 [103] | Paclitaxel + Trastuzumab + Pertuzumab + Atezolizumab | III | Metastatic | Recruiting | Immune check point inhibitor | Anti PD-L1 |
NCT02297698 [104] | Nelipepimut+ Trastuzumab | II | Metastatic | Active, not recruiting | Vaccine | Peptide-based vaccine (E75) |
NCT00266110 [105] | therapeutic autologous dendritic cells+ Trastuzumb + Chemotherapy | II | Metastatic | Completed | Vaccine | DC vaccine |
NCT02713984 [106] | Anti-HER2 CAR-T | I | Metastatic | Recruiting | Vaccine | CAR-T cells |
NCT03125928 [107] | Pertuzumab + Trastuzumab + Atezolizumab | IIA | Metastatic | Recruiting | Immune check point inhibitor | Anti PD-L1 |
NCT02605915 [108] | Atezolizumab+ Pertuzumab + Trastuzumab + or Atezolizumab+TDM-1 | IB | Early and metastatic | Active, not recruiting | Immune check point inhibitor | Anti PD-L1 |
NCT03417544 [109] | Atezolizumab+Pertuzumab + Trastuzumab + | II† | Metastatic | Recruiting | Immune check point inhibitor | Anti PD-L1 |
NCT00343109 [110] | NA | II | Metastatic | Active, not recruiting | Vaccine | ICD peptide-based vaccine |
NCT02547961 [111] | NA | I/II | Metastatic | Completed | Vaccine | CAR-T cells |
NCT03364348 [112] | Utomilumab + TDM-1 or trastuzumab | I | Metastatic | Recruiting | Immune costimulatory | T-Cell activation |
NCT01922921 [113] | I/II | Metastatic | Active, not recruiting | Vaccine | ICD peptide-based vaccine | |
NCT03032107 [114] | Pembrolizumab+ TDM-1 | I | Metastatic | Recruiting | Immune checkpoint inhibitor | Anti PD-1 |
NCT00436254 [115] | NA | I | Early and metastatic | Active, not recruiting | Vaccine | pNGVL3-hICD vaccine |
NCT00194714 [116] | NA | I/II | Metastatic | Active, not recruiting | Vaccine | Her2+ peptide vaccine |
NCT03740256 [117] | NA | I | Metastatic | Not yet recruiting | Vaccine | Adenovirus-specific cytotoxic T lymphocytes (HER2-AdVST), in combination with intra-tumor injection of CAdVEC, an oncolytic adenovirus |